Cargando…

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

PURPOSE: Nivolumab and pembrolizumab are antibodies against the programmed-death-receptor- 1 (PD-1) which are associated with distinct immune related adverse effects (AEs). This meta-analysis of randomized clinical trials aims to summarize current knowledge regarding the toxicity profile of these ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352453/ https://www.ncbi.nlm.nih.gov/pubmed/27852042 http://dx.doi.org/10.18632/oncotarget.13315

Ejemplares similares

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
por: Chae, Young Kwang, et al.
Publicado: (2016)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

FGFR3-TACC3 fusion in solid tumors: mini review
por: Costa, Ricardo, et al.
Publicado: (2016)

Genomic characterization of high-risk non-muscle invasive bladder cancer
por: Meeks, Joshua J., et al.
Publicado: (2016)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
por: Costa, Ricardo, et al.
Publicado: (2016)

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities
por: Costa, Ricardo, et al.
Publicado: (2017)

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
por: Chae, Young Kwang, et al.
Publicado: (2016)

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
por: Costa, Ricardo, et al.
Publicado: (2016)

The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer
por: Pharaon, Rebecca R., et al.
Publicado: (2021)

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
por: Chae, Young Kwang, et al.
Publicado: (2017)

Monoclonal Antibodies Approved for Cancer Therapy
por: Baldo, Brian A.
Publicado: (2016)

The challenge of developmental therapeutics for adrenocortical carcinoma
por: Costa, Ricardo, et al.
Publicado: (2016)

Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
por: Chae, Young Kwang, et al.
Publicado: (2018)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Wnt/beta-catenin pathway: modulating anticancer immune response
por: Pai, Sachin Gopalkrishna, et al.
Publicado: (2017)

Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections
por: Reichert, Janice M.
Publicado: (2012)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis
por: Li, Han, et al.
Publicado: (2021)

Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
por: Françoso, Alex, et al.
Publicado: (2017)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
por: Cona, Maria Silvia, et al.
Publicado: (2019)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
por: Chuzi, Sarah, et al.
Publicado: (2017)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
por: Tshiani Mbaya, Olivier, et al.
Publicado: (2021)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives
por: Forgie, Benjamin N., et al.
Publicado: (2022)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
por: Santa-Maria, Cesar August, et al.
Publicado: (2018)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires
por: Petersen, Brian M., et al.
Publicado: (2021)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
por: Choi, Jin Wook, et al.
Publicado: (2020)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer
por: Chae, Young Kwang, et al.
Publicado: (2016)

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
por: Villaflor, Victoria M., et al.
Publicado: (2013)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
por: Pathak, Ranjan, et al.
Publicado: (2021)

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
por: Psilopatis, Iason, et al.
Publicado: (2023)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_53nfpmh4e0ijadaqsfnu1roh94